David L. Greenwood, Chairman
Eric H. Bjerkholt
Bhaskar Chaudhuri, Ph.D.
As Chief Executive Officer of Dow, Dr. Chaudhuri led the company through a transition from a contract development focus to developing an attractive internal product pipeline and the company’s eventual merger with Valeant. Dr. Chaudhuri holds a Ph.D. in Physical Pharmacy, an M.S. in Industrial Pharmacy and a B.S. in Pharmacy.
Mr. Eastman joined Essex Woodlands in October 2006. He serves as Chairman of the board of directors at Elusys Therapeutics and on the board of directors at Revance Therapeutics, IntegenX Inc. and Symphogen A/S. He has served on the Board at The Buck Institute, the largest non-profit research institute in the U.S. studying diseases of aging. Mr. Eastman earned a B.A. from Williams College and an M.B.A. from Columbia University.
Phyllis Gardner, M.D.
Dr. Gardner also worked with Essex Woodlands from 1999 until 2014, where her expertise in pharmacology and drug delivery was invaluable to the firm in evaluating technology in this growing segment of the pharmaceutical sector. She has received numerous national awards and honors and serves on the Board of Directors of Revance Therapeutics, Inc. as well as the Harvard Medical School Board of Fellows. Dr. Gardner previously served on the Board of Directors of Parnell Pharmaceuticals Holdings Ltd, Aerogen Inc. (acquired by Nektar Pharmaceuticals), and BioMarin Pharmaceuticals, as well as numerous private company boards.
Dr. Gardner holds a B.S. from the University of Illinois, where she graduated Bronze Tablet, Phi Beta Kappa and Phi Kappa Phi, and an M.D. from Harvard Medical School, where she graduated Alpha Omega Alpha. She trained in internal medicine at Massachusetts General Hospital, followed by a Chief Residency at Stanford University Medical Center. Dr. Gardner completed research fellowships at the College of Physicians and Surgeons at Columbia University and University College, London, U.K
Ivan Gergel, M.D.
Dr. Gergel received his M.D. from The Royal Free Medical School of The University of London and an MBA from the Wharton School of the University of Pennsylvania.
Paul Goddard, Ph.D.
Dr. Goddard served as lead director on the board of Onyx Pharmaceuticals (a subsidiary of Amgen) and on the boards of several other companies including Adolor Corporation, A.P. Pharma, Molecular Devices and Xenoport. Dr. Goddard completed his Ph.D. in the area of Etiology and Pathophysiology of colon cancer at St. Mary’s Hospital, University of London.
Peter D. Staple, President and Chief Executive Officer
Prior to joining ALZA, Mr. Staple served in senior positions at Cetus and Chiron Corporations, where his responsibilities covered corporate partnering, licensing, mergers and acquisitions, and financings, including transactions involving commercialization of polymerase chain reaction, and screening technologies for hepatitis C and human immunodeficiency viruses. Prior to entering the biotechnology industry, Mr. Staple practiced corporate and securities law with Heller Ehrman LLP. Mr. Staple is Chairman of the board of directors of Depomed, Inc., and has served multiple terms on the board of visitors at Stanford Law School. He holds B.A. and J.D. degrees from Stanford University.